Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

ClinicalTrials.gov ID: NCT05489211

Public ClinicalTrials.gov record NCT05489211. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 10:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Study identification

NCT ID: NCT05489211
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 454 participants

Conditions and interventions

Conditions

Interventions

5-Fluorouracil Drug
Bevacizumab Drug
Capecitabine Drug
Carboplatin Drug
Cisplatin Drug
Datopotamab deruxtecan (Dato-DXd) Drug
Prednisone/ prednisolone Drug
Rilvegostomig Drug
Volrustomig Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 5, 2022
Primary completion: Sep 30, 2027
Completion: Sep 30, 2027
Last update posted: Mar 18, 2026

2022 – 2027

United States locations

U.S. sites: 18
U.S. states: 13
U.S. cities: 16

Facility	City	State	ZIP	Site status
Research Site	Los Angeles	California	90095	Recruiting
Research Site	San Diego	California	92103	Withdrawn
Research Site	Santa Rosa	California	95403	Recruiting
Research Site	Muncie	Indiana	47303	Withdrawn
Research Site	Kansas City	Kansas	66160	Withdrawn
Research Site	Boston	Massachusetts	02114	Withdrawn
Research Site	Boston	Massachusetts	02215	Completed
Research Site	Grand Rapids	Michigan	49503	Recruiting
Research Site	East Brunswick	New Jersey	08816	Recruiting
Research Site	Albuquerque	New Mexico	87109	Recruiting
Research Site	Commack	New York	11725	Recruiting
Research Site	Cincinnati	Ohio	45219	Recruiting
Research Site	Columbus	Ohio	43219	Recruiting
Research Site	Portland	Oregon	97239	Withdrawn
Research Site	Nashville	Tennessee	37203	Recruiting
Research Site	Nashville	Tennessee	37232	Withdrawn
Research Site	Houston	Texas	77030	Recruiting
Research Site	Madison	Wisconsin	53792	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 76 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05489211, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Mar 18, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05489211 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →